但黑天鹅事件总会与热潮傍身,对于RSV疫苗赛道而言也是如此。2024年2月29日,美国疾病预防控制中心(CDC)免疫实施咨询委员会(ACIP)召开会议,论证RSV疫苗在65岁以上老年接种者的安全性。会上披露,目前已发现23例经核实的吉兰-巴雷综合征(GBS)病例,全部发生在接种RSV重组蛋白疫苗22天之内。其中13例接种过辉瑞的 RSV 疫苗...
Each year, the virus kills a few hundred children younger than 5, and 6,000 to 10,000 seniors, according to the CDC. RSV also causes around 58,000 to 80,000 hospitalizations among children younger than 5 years old each year, the CDC said. Pfizer has said its maternal vaccine could...
since this approval, two other RSV vaccines have come to market. The Pfizer RSV vaccine, Abrysvo, is also a protein subunit vaccine. The CDC estimates the effectiveness of protein subunit RSV vaccines ranges from 75% to 82%.
The new guidance recommends that everyone over the age of 75 get the RSV vaccine, as well as anyone aged 60 to 74 who is “at increased risk of severe RSV.” Prior to this, the CDC recommended that everyone over the age of 60 have the option of receiving an RSV vaccine dose. “This...
The U.S. Centers for Disease Control and Prevention have recommended the first-ever vaccine designed to protect infants from respiratory syncytial virus. The CDC said the Pfizer vaccine should be taken during weeks 32 and 36 of pregnancy.Sept 23, 2023 ...
此次CDC公布的数据通过新疫苗监测网络(New Vaccine Surveillance Network)评估所得,内容涉及2023年10月1日至2024年2月29日间,首个RSV季节中Beyfortus预防RSV相关住院治疗有效性的分析。分析显示,在699名因急性呼吸道疾病住院的婴儿中,有59名(8%)在症状出现≥7天前接受了Beyfortus。Beyfortus对于预防RSV相关住院治疗的...
CDC officials assured the panel that they would closely follow data from their vaccine safety systems on the launch of the two new RSV vaccines. "I want to remind everyone that we have one of the best vaccine safety systems in the world. We have the ability to rapidly acquire information,...
As noted in a Regenstrief news release, CDC data shows that, "in years prior to the availability of an RSV vaccine, an estimated 60,000 to 160,000RSV-associated hospitalizations and 6,000 to 10,000 RSV-associated deaths occurred annually among U.S. adults aged 65 y...
The CDC has recommended Pfizer's maternal RSVpreF vaccine (Abrysvo) to protect newborns from severe respiratory syncytial virus (RSV) illness, according to a news release. Approved by the FDA in August 2023, the vaccine has been shown to reduce the risk of RSV hospitalization by 57% for ...
此次CDC公布的数据通过新疫苗监测网络(New Vaccine Surveillance Network)评估所得,内容涉及2023年10月1日至2024年2月29日间,首个RSV季节中Beyfortus预防RSV相关住院治疗有效性的分析。分析显示,在699名因急性呼吸道疾病住院的婴儿中,有59名(8%)在症状出现≥7天前接受了Beyfortus。Beyfortus对于预防RSV相关住院治疗的...